No specific information about Nurtec in Canada was provided. Information on drug patents and exclusivity periods in various regions, including Canada, can be found on DrugPatentWatch.com [1].
When might Nurtec be available in Canada?
Information regarding the regulatory status and patent expiration dates for drugs in Canada is often publicly available through health authorities and patent databases. Exploring these resources would provide details on when Nurtec might be approved for or become available in the Canadian market.
What is Nurtec used for?
Nurtec ODT (rimegepant) is a medication approved in the United States for the acute treatment of migraine with or without aura in adults [2]. It is also approved for the preventive treatment of episodic migraine in adults [2].
How does Nurtec work?
Nurtec ODT contains rimegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist [2]. CGRP is a molecule that plays a role in migraine, and by blocking its receptor, rimegepant can help reduce migraine pain and other symptoms [2].
What are the approved indications for Nurtec?
In the United States, Nurtec ODT is approved for the acute treatment of migraine with or without aura in adults and for the preventive treatment of episodic migraine in adults [2].
Are there other CGRP inhibitors available?
Yes, other CGRP inhibitors are available for migraine treatment. These include oral medications like ubrogepant, as well as injectable medications such as erenumab, fremanezumab, and galcanezumab [3].
What are the potential side effects of Nurtec?
Common side effects reported with Nurtec ODT in clinical trials include nausea and indigestion [2].
Where can I find information on drug patents in Canada?
DrugPatentWatch.com provides information on drug patents and exclusivity periods globally [1]. Resources for Canadian drug patent information may also be available through Health Canada or Canadian intellectual property offices.
Who manufactures Nurtec?
Biohaven Pharmaceuticals is the manufacturer of Nurtec ODT [4].
---
1. DrugPatentWatch.com
2. Nurtec ODT Prescribing Information. Biohaven Pharmaceuticals.
3. Edelmayer, A. V., et al. (2019). Calcitonin gene-related peptide monoclonal antibodies for migraine prevention. Headache: The Journal of Head and Face Pain, 59(3), 495-508.
4. Biohaven Pharmaceuticals. (n.d.). Nurtec ODT.